Ascensia launches Eversense 365
By HME News Staff
Updated 10:25 AM CDT, Thu October 3, 2024
PARSIPPANY, N.J. – Ascensia Diabetes Care has launched its Eversense 365 continuous glucose monitoring system, which received clearance from the U.S. Food and Drug Administration in September. “Eversense offers a completely differentiated CGM experience, overcoming many of the frustrations experienced with traditional, short-term CGMs, such as early failure, disruptive false alerts and skin irritation,” said Brian Hansen, president of CGM at Ascensia. “With only one CGM replacement a year, fewer failed or wasted sensors, and alerts you can trust, Eversense 365 allows patients to live life uninterrupted by their diabetes technology.” The Eversense 365 CGM has been approved by the FDA for Type 1 and Type 2 diabetes for people aged 18 years and older. It has been approved as an integrated CGM system, meaning it can integrate with compatible medical devices, including insulin pumps, as part of an automated insulin delivery system.
Comments